Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06416267
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-07
Brief Title:
Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis LC MBL
Sponsor:
University of Haifa
Organization:
University of Haifa
Study Overview
Official Title:
Immune Biomarkers Genetic Risk and the Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis LC MBL
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MBL RiskConseq
Brief Summary:
The aim of this proposal is to identify immune biomarkers genetic risk and the clinical consequences of low count monoclonal B-cell lymphocytosis LC MBL a common premalignant condition affecting up to 17 of European adults ageampgt40 LC MBL is a precursor to chronic lymphocytic leukemia CLL characterized by a circulating population of clonal B-cells It is relatively understudied despite emerging evidence of clinical consequences such as increased risk for life-threatening infections and lymphoid malignancies Studies reported that male sex age family history of CLL and CLL-susceptibility genetic loci were associated with LC MBL risk These findings were reported in European ancestry individuals and have not been generalized to other thnicities This study will provide this missing knowledge using a unique multi-ethnic Israeli population of Jews and Arabs that have one of the highest and lowest age-standardized incidence rates of CLL in the world respectively and characterized with different genetic backgrounds
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None